Clinical Trial

Dexmedetomidine Supplemented Analgesia and Long-term Survival After Cancer Surgery

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
A majority of the elderly patients undergo surgery for malignant tumors. For these patients, postoperative tumor recurrence and metastasis are main factors that worsen long-term outcomes. The investigators hypothesize that dexmedetomidine supplemented analgesia in elderly patients after cancer surgery may help to maintain immune function and improve long-term outcomes, possibly by relieving stress and inflammatory response, improving analgesic efficacy and sleep quality, and reducing delirium incidence.
Protocol Amendment History 1 change
critical Sponsor refiled this as active, not recruiting (was completed) 2026-07-29
Trial Details
NCT Number NCT03012971
Lead Sponsor Peking University First Hospital
Collaborators: Affiliated Hospital of Hebei University, Qingdao Municipal Hospital, The Second Affiliated Hospital of Air Force Military Medical University, Peking University International Hospital, Guizhou Provincial People's Hospital, The Third Xiangya Hospital of Central South University, Shanxi Province Cancer Hospital, Tianjin Nankai Hospital, Fuling Central Hospital of Chongqing City, Tianjin Third Central Hospital, Xiyuan Hospital of China Academy of Chinese Medical Sciences
Conditions Elderly, Surgery, Analgesia, Dexmedetomidine, Long-term Outcome
Enrollment 1,500 participants
Start Date 2017-01-06
Primary Completion 2026-12-11 (estimated)
Study Completion 2026-12-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-28